Endocan Corporation (ENDO) CFO and Sr. VP of Business Development, Robert Kane, Interviewed on 'StockRadio.com' Regarding Company Developments and Forward Looking Strategy for 2014

COLORADO SPRINGS, Colo., Nov. 8, 2013 /PRNewswire/ -- Endocan Corporation (NASDAQ OTC: ENDO), a U.S. Company specializing in cannabis and cannabinoid formulation-based health and wellness solutions, is pleased to announce that Robert Kane, CFO and Sr. VP of Business Development, speaks to StockRadio.com with respect to Endocan's latest developments and overall strategy to make 2014 a historic year.

The interview is available at http://thestockradio.com and will also be posted on the Company's social media outlets:  Facebook, Twitter, and Google+.

"Endocan is a young company progressing quickly in a dynamic and highly profitable industry.  Extra time and effort has been placed on making sure every step is being executed properly with a full understanding of the regulatory and constantly changing environment in which we operate, with a recent focus on our major branding campaign.  We appreciate TheStockRadio.Com and its audience for taking their valuable time to listen to an overview of our patient-focused story, which is still available at TheStockRadio.Com website," stated Robert Kane, CFO & Sr. VP of Business Development, Endocan Corporation.

About The StockRadio.Com
The StockRadio.com is a small-cap research and investment commentary provider. TheStockRadio.com strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on TheStockRadio, please visit http://thestockradio.com.

About Endocan Corporation
The brand name Endocan™ was chosen by the Board of Directors as a direct reference to the endocannabinoid system of the human body. The endocannabinoid system is a group of neuromodulatory compounds and their receptors that are involved in a variety of fundamental physiological processes including pain-sensation, immune function, stress, sleep, mood, appetite, and memory. Cannabinoids from plants, including those found in the Cannabis genus, as well as those autonomously produced within living biological systems, work together in the operation of the endocannabinoid system. The modulation of this system is the basis for cannabinoid-based medical treatments to assist patients to improve their health and well-being.

Endocan Corporation (FKA The X-Change Corporation and as XCHC) is currently developing new natural cannabis-based products based on innovative formulations to utilize the unique and potent benefits of the cannabis and hemp plants. Medicinal properties of cannabis and hemp have been known and applied for thousands of years. With the aid of scientific research, Endocan Corporation is translating such knowledge into development of effective cannabinoid formulation-based health and wellness solutions as well as cosmeceutical, nutraceutical, and food brands throughout the world. The Company's health and wellness, nutritional, and cosmetics lines will address personal needs and will evolve with the introduction of new formulations and products, advancing the Company within the expanding multibillion-dollar global market.

TheStockRadio.com Disclosure TheStockRadio.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. TheStockRadio.com is a Web site wholly owned by Allan James Group. Neither theStockRadio.com nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. Please read our report and visit our Web site, TheStockRadio.com, for complete risks and disclosures.

Contact: [email protected]

Forward Looking Statements This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing words such as "anticipate," "seek," intend," "believe," "plan," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. The Company does not undertake any duty nor does it intend to update the results of these forward-looking statements.

Endocan Corporation
President
Dr. Dorothy Bray
[email protected] 
www.endocan.com 
+1.866.326.5595

Investment Inquiries
Robert Kane
CFO, Sr Vp of Business Development
[email protected]
+1.561.420.4824

SOURCE Endocan Corporation